Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: A prospective cohort study

Journal of Microbiology, Immunology and Infection

Volumn 48, Issue 2, 2015, Pages 168-174

  Kung, Che Hsuan ^a,b   Ku, Wen Wei ^a   Lee, Chi Hung ^a,c   Fung, Chang Phone ^a,c   Kuo, Shu Chen ^a,c,d   Chen, Te Li ^c   Lee, Yi Tzu ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Community onset; Extended spectrum lactamase; Urinary tract infection

Indexed keywords

AMIKACIN; AMPICILLIN; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERTAPENEM; FLOMOXEF; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; BETA LACTAMASE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; COHORT ANALYSIS; COMMUNITY ONSET URINARY TRACT INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY WARD; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENOTYPE; HOSPITALIZATION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MASS SPECTROMETER; MEDICAL RECORD REVIEW; NASOGASTRIC TUBE; PHENOTYPE; PROSPECTIVE STUDY; RISK FACTOR; TAIWAN; URINARY TRACT INFECTION; URINE CULTURE; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; FEMALE; GENETICS; MALE; MICROBIAL SENSITIVITY TEST; POLYMERASE CHAIN REACTION; SECRETION (PROCESS); UNIVERSITY HOSPITAL; URINARY TRACT INFECTIONS;

ACADEMIC MEDICAL CENTERS; ADULT; BETA-LACTAMASES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; URINARY TRACT INFECTIONS;

EID: 84924625796     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.08.006     Document Type: Article

References (40)

1. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
2. Wiener J., Quinn J.P., Bradford P.A., Goering R.V., Nathan C., Bush K., et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999, 281:517-523.
3. Pitout J.D., Nordmann P., Laupland K.B., Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56:52-59.
4. Rodríguez-Baño J., Navarro M.D. Extended-spectrum β-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 2008, 14(Suppl. 1):104-110.
5. Yang Y.S., Ku C.H., Lin J.C., Shang S.T., Chiu C.H., Yeh K.M., et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect 2010, 43:194-199.
6. Calbo E., Romani V., Xercavins M., Gomez L., Vidal C.G., Quintana S., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006, 57:780-783.
7. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
8. Lee D.S., Lee C.B., Lee S.J. Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol 2010, 51:492-497.
9. Performance standards for antimicrobial susceptibility testing 2009, Clinical and Laboratory Standards Institute, Supplement M100-S19, Clinical and Laboratory Standard Institute, Wayne, PA.
10. Munier G.K., Johnson C.L., Snyder J.W., Moland E.S., Hanson N.D., Thomson K.S. Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs. J Clin Microbiol 2010, 48:673-674.
11. Bell J.M., Chitsaz M., Turnidge J.D., Barton M., Walters L.J., Jones R.N. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 2007, 45:1478-1482.
12. Steward C.D., Rasheed J.K., Hubert S.K., Biddle J.W., Raney P.M., Anderson G.J., et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 2001, 39:2864-2872.
13. Kjerulf A., Hansen D.S., Sandvang D., Hansen F., Frimodt-Møller N. The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark. APMIS 2008, 116:118-124.
14. Jeong S.H., Song W., Park M.J., Kim J.S., Kim H.S., Bae I.K., et al. Boronic acid disk tests for identification of extended-spectrum beta-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases. Int J Antimicrob Agents 2008, 31:467-471.
15. Song W., Jeong S.H., Kim J.S., Kim H.S., Shin D.H., Roh K.H., et al. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extended-spectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect Dis 2007, 57:315-318.
16. Song W., Bae I.K., Lee Y.N., Lee C.H., Lee S.H., Jeong S.H. Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol 2007, 45:1180-1184.
17. Poirel L., Le Thomas I., Naas T., Karim A., Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000, 44:622-632.
18. Brasme L., Nordmann P., Fidel F., Lartigue M.F., Bajolet O., Poirel L., et al. Incidence of class A extended-spectrum beta-lactamases in Champagne-Ardenne (France): a 1 year prospective study. J Antimicrob Chemother 2007, 60:956-964.
19. Kang C.I., Wi Y.M., Lee M.Y., Ko K.S., Chung D.R., Peck K.R., et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol 2012, 50:312-317.
20. Luzzaro F., Mezzatesta M., Mugnaioli C., Perilli M., Stefani S., Amicosante G., et al. Trends in production of extended-spectrum β-lactamases among Enterobacteria of medical interest: report of the second Italian Nationwide Survey. J Clin Microbiol 2006, 44:1659-1664.
21. Coque T.M., Baquero F., Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008, 13. pii=19044.
22. Hansen D.S., Schumacher H., Hansen F., Stegger M., Hertz F.B., Schonning K., et al. Extended-spectrum beta-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, beta-lactamase distribution, phylogroups, and co-resistance. Scand J Infect Dis 2012, 44:174-181.
23. Yamasaki K., Komatsu M., Yamashita T., Shimakawa K., Ura T., Nishio H., et al. Production of CTX-M-3 extended-spectrum β-lactamase and IMP-1 metallo β-lactamase by five Gram-negative bacilli: survey of clinical isolates from seven laboratories collected in 1998 and 2000, in the Kinki region of Japan. J Antimicrob Chemother 2003, 51:631-638.
24. Bonnet R. Growing group of rxtended-dpectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48:1-14.
25. Wang H., Kelkar S., Wu W., Chen M., Quinn J.P. Clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother 2003, 47:790-793.
26. Radice M., Power P., Di Conza J., Gutkind G. Early dissemination of CTX-M-derived enzymes in South America. Antimicrob Agents Chemother 2002, 46:602-604.
27. Palucha A., Mikiewicz B., Hryniewicz W., Gniadkowski M. Concurrent outbreaks of extended-spectrum β-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J Antimicrob Chemother 1999, 44:489-499.
28. Cantón R., Coque T.M. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
29. Chanawong A., M'Zali F.H., Heritage J., Xiong J.-H., Hawkey P.M. Three Cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother 2002, 46:630-637.
30. Yan J.J., Ko W.C., Tsai S.H., Wu H.M., Jin Y.T., Wu J.J. Dissemination of CTX-M-3 and CMY-2 beta-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol 2000, 38:4320-4325.
31. Tofteland S., Haldorsen B., Dahl K.H., Simonsen G.S., Steinbakk M., Walsh T.R., et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007, 45:199-205.
32. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
33. Yu W.L., Chuang Y.C., Walther-Rasmussen J. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006, 39:264-277.
34. Rupp M.E., Fey P.D. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63:353-365.
35. Medeiros A.A. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997, 24(Suppl. 1):S19-S45.
36. Ramphal R., Ambrose P.G. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006, 42:S164-S172.
37. Wu Y.H., Chen P.L., Hung Y.P., Ko W.C. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. J Microbiol Immunol Infect 2014, 47:197-203.
38. Asensio A., Oliver A., Gonzalez-Diego P., Baquero F., Pérez-Díaz J.C., Ros P., et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis 2000, 30:55-60.
39. Dziekan G., Hahn A., Thüne K., Schwarzer G., Schäfer K., Daschner F.D., et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000, 46:263-270.
40. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002, 49:999-1005.